ALINA: Another stepping stone toward a future of LDCT lung cancer screening in never-smokers?
Med
; 5(7): 649-651, 2024 Jul 12.
Article
in En
| MEDLINE
| ID: mdl-39002534
ABSTRACT
The ALINA trial1 demonstrated that 2 years of adjuvant alectinib achieved statistically significantly improved 2-year overall and central nervous system (CNS) disease-free survival over platinum-doublet chemotherapy in resected early-stage (IB ≥ 4 cm to IIIA) ALK+ non-small cell lung cancer (NSCLC). Identifying early-stage ALK+ NSCLC patients (60% were never-smokers in the ALINA trial) may require low-dose computed tomography (LDCT) lung cancer screening in never-smokers.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Tomography, X-Ray Computed
/
Carcinoma, Non-Small-Cell Lung
/
Early Detection of Cancer
/
Lung Neoplasms
Limits:
Humans
Language:
En
Journal:
Med
Year:
2024
Document type:
Article
Country of publication:
Estados Unidos